Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 mai 2018 09h18 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, May 10, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare...
09 mai 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation

Lead product candidate, KB103, shown to successfully transfer COL7A1 gene and to correct recessive dystrophic epidermolysis bullosa (RDEB) PITTSBURGH, May 09, 2018 (GLOBE NEWSWIRE) -- Krystal...
07 mai 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update

IND for KB103 to treat dystrophic epidermolysis bullosa (DEB) cleared by FDA Patient enrollment in Phase 1/2 study of KB103 to begin in May 2018 at Stanford University Krystal Biotech’s KB103...
26 avr. 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa

KB103 is the first-ever herpes simplex virus (HSV-1) based topical gene therapy candidate engineered to produce human collagen protein to treat dystrophic epidermolysis bullosa (DEB) The planned...
19 avr. 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa

KB103 represents the first investigational HSV-1 based gene therapy for the severe skin disorder dystrophic epidermolysis bullosa to receive this designation KB103 previously received Orphan Drug...
18 avr. 2018 16h01 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA

PITTSBURGH, April 18, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, today...
27 mars 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa

KB103 is an internally generated modified HSV-1 based gene therapy candidate engineered with a COL7A1 gene construct to treat Dystrophic Epidermolysis Bullosa (DEB) Therapeutic candidate formulated...
12 mars 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech Reports 2017 Financial Results and Business Progress

IND for KB103 to treat Dystrophic Epidermolysis Bullosa (DEB) to be filed in March 2018 IND for KB105 to treat Lamellar Ichthyosis to be filed in Q4 2018 Company was granted composition of matter...
05 mars 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech, Inc. to Present at the 30th Annual ROTH Conference

PITTSBURGH, March 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today...
16 janv. 2018 08h00 HE | Source: Krystal Biotech, Inc.

Krystal Biotech, Inc. Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases

PITTSBURGH, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that the...

Page précédente